post-mastectomy rt after neoadjuvant chemotherapy (nac)€¦ · post-mastectomy rt after...
TRANSCRIPT
![Page 1: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/1.jpg)
Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)
Jay R. Harris, M.D.Dana-Farber Cancer InstituteBrigham and Women’s HospitalHarvard Medical School
![Page 2: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/2.jpg)
Conclusions
• When considering PMRT, use both initial clinical and final path stages
• If LABC, give PMRT even if pCR• If ypN+, give PMRT• If early stage with pCR, no PMRT
• After mastectomy, survival gain isn’t linked to LRR risk → need RCT’s
![Page 3: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/3.jpg)
Neoadjuvant Chemotherapy (NAC)
It is ironic that NAC, which was developed in the hope of improving the results of chemotherapy, has had its major practical impact on improved (i.e., less) local therapy
![Page 4: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/4.jpg)
Major Issues regarding RT after NAC
• The guidelines for the use of RT after NAC are not well established
• Which patients are appropriate for BCT?
• Which patients are appropriate for PMRT?
![Page 5: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/5.jpg)
Timing of SNB
• Many radiation oncologists in the U.S. favor doing SNB prior to NAC
• However, the advantages of delayed SNB clearly outweigh the disadvantages
• These include 1 not 2 operations, ability to assess response , and fewer ALND’s
![Page 6: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/6.jpg)
Axillary Staging Prior to NAC
• We also favor axillary US and FNA if suspicious
• With FNA+, there is increasing evidence that delayed SNB is a viable option
• This is particularly true with use of dual tracer and resection of at least 2 SLNs
![Page 7: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/7.jpg)
Which patients are appropriate for PMRT?
• This is a harder question and we are still getting data on this issue
• So far, we have learned that the need for PMRT is determined both by the initial clinical stage and the final path stage
![Page 8: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/8.jpg)
LR after NAC followed by Mastectomy and no RT (MD Anderson)
• Retrospective analysis of 150 patients treated with either pre -op Doxuribicin regimen or Paclitaxel without post-op RT
• Stage: I - 1%; II - 43%; IIIA - 23%;IIIB - 25%; and IV - 7 %
(Ref: Buchholz TA et al. IJROBP0: 53; 880, 2002)
![Page 9: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/9.jpg)
NAC and MRM, No RT
• Crude 5 -Yr LR related to pN:0+: 10% 1-3+: 17% 4-9+: 47%
• These LR rates after NAC by nodal stageare greater than rates after initial surgery
• NB: Among 18 patients with pT&N CR, the 5-Yr rate of LR = 19%
![Page 10: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/10.jpg)
5-Year LR by # + Nodes:Post-op vs. Pre -op
0
10
20
30
40
50
60
0 +LN 1-3 +LN >3 +LN
ADJNEO
p=0.143 p=0.087 p=0.001
7%12%
10%
18%23%
53%
![Page 11: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/11.jpg)
Matching Patients by Clinical Stage
• Clinical stage was more advanced for pre -op patients than for post-op patients and later matched by clinical stage
• Much, but not all, of the difference in LR is corrected by use of clinical stage
![Page 12: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/12.jpg)
5-Year LR by # + Nodes:Post-op vs. Pre -op (matched by cTN)
0
5
10
15
20
25
30
35
0 +LN 1-3 +LN >3+LN
ADJNEO
P=NS P=NS P=NS
0%
5%
12%14%
21%
31%
![Page 13: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/13.jpg)
Clinical Implication
• Path stage after PST does not have the same prognostic value for LR as the same path stage with initial surgery
• Key Observation: Both the initial clinical and the final pathologic stage must be used to determine the LR risk
![Page 14: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/14.jpg)
Implications: Pre -op Ctx + MRM
• LABC patients should receive PMRT regardless of final path findings
• Use of PMRT in Stage I/II patients with 1-3+ nodes after NAC less well defined
• Experience from NSABP is most informative
![Page 15: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/15.jpg)
• Includes the preop AC arm from B -18 and and the preop AC +/- T arms from B -27
• Analysis is based on 1,071 mastectomy patients with 131 LR’s
• SNB performed after NAC; pCR was defined as no residual invasive disease
NSABP Experience
Ref: Mamounas E et al JCO 2012 30: 3960
![Page 16: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/16.jpg)
MVA: Predictors of LRR after Mastectomy
• Clinical tumor size at presentation
• Clinical node status at presentation
• Path node status after PST
• Path response in the breast
Both the initial clinical and the final path stage must be used to determine LR risk
![Page 17: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/17.jpg)
MVA
Variable HR 95% CI P
cT: > 5 v < 5 cm 1.58 1.12 – 2.23 .0095
cN+ v cN- 1.53 1.08 - 2.18 .017
ypN-/no breast pCR vypN-/breast pCR
2.21 0.77 – 6.30 < .001
ypN+ vypN-/breast pCR
4.48 1.64 – 12.21 < .001
![Page 18: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/18.jpg)
©2012 by American Society of Clinical Oncology
(A) MastexT ≤ 5-cm
(B) MastexT > 5-cm
Notes:
Any ypN+ →LRR > 10%
pCR →LRR is low
ypN+pCR
![Page 19: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/19.jpg)
Which patients should get PMRT?
• The need for PMRT is determined by the initial cStage and the final pStage
• LABC patients should get PMRT even pCR
• Any ypN+ patient should get PMRT
• Operable patients with pCR should not
• Patients with ypN -/no breast pCR: ? PMRT
![Page 20: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/20.jpg)
? PMRT with ypN -/no breast pCR
• Consider degree of response (MP, RCB)
• Consider especially in -/-/- patients
• Consider in younger patients with less competing risks
![Page 21: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/21.jpg)
Who get a Survival Gain from PMRT?
• It was initially thought that reduction in LRR was linked to survival gain (2005)
• So called 4 to 1 ratio between reduction in LRR at 5 years and survival gain at 15 yrs
• Newer data from EBCTCG and others no longer shows this linkage
![Page 22: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/22.jpg)
Newer Data on LRR and Survival Gain
• Updated data from EBCTCG now shows greater survival gain for PMRT with 1 -3+ nodes than with > 3+ nodes even though greater reduction in LRR with > 3+ nodes
• This is supported by results from MA.20
Refs: EBCTCG Preliminary Data shown 2012Whelan T et al, ASCO 2011 abstract
![Page 23: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/23.jpg)
Trials of Mast+AD ±RT (EBCTCG)
• Reduction in recurrence (LR or DM) is similar for patients with 1 -3+ vs > 4+ nodes, but improvement in survival is somewhat greater in 1 -3+ patients
• This is due to the greater competing risk of DM in the > 4+ patients
![Page 24: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/24.jpg)
10-year gain 11.4 % (SE 2.9)
Mast+AD+RT 34.4%
35.0
24.8
Mast+AD 45.8%
1314 women
0
10
20
30
40
50
60
AN
Y F
IRS
T R
EC
UR
RE
NC
E (%
)
0 5 10Years since randomisation
RECURRENCE
15-year gain 9.4 % (SE 2.9)logrank 2p = 0.005
Mast+AD+RT 36.2%
21.1
17.2
35.4
29.6
Mast+AD 45.6%
1314 women
0
10
20
30
40
50
60
BR
EA
ST
CA
NC
ER
MO
RT
ALI
TY
(%
)
0 5 10 15Years since randomisation
BREAST CANCER MORTALITY
24
65% had chemotherapy, mostly CMF
Trials of Mast+AD ±RT: pN1 -3, full AD
![Page 25: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/25.jpg)
10-year gain 9.1 % (SE 2.7)
Mast+AD+RT 65.9%
65.5
57.1
Mast+AD 75.0%1652 women
0
10
20
30
40
50
60
AN
Y F
IRS
T R
EC
UR
RE
NC
E (%
)
0 5 10Years since randomisation
RECURRENCE
15-year gain 2.3 % (SE 2.9)logrank 2p > 0.1; NS
Mast+AD+RT 66.4%
46.9
45.6
63.4
59.0
Mast+AD 68.7%
1652 women
0
10
20
30
40
50
60
BR
EA
ST
CA
NC
ER
MO
RT
ALI
TY
(%
)
0 5 10 15Years since randomisation
BREAST CANCER MORTALITY
25
80% had chemotherapy, mostly CMF
Trials of Mast+AD ±RT: pN4+ full AD
![Page 26: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/26.jpg)
Updated EBCTCG Results
• The survival benefit of PMRT is not linked to reduction in LR → Need RCT’s
• PMRT is at least as beneficial in patients with 1 -3+ as in > 4 + nodes
• Impact of chemotherapy unclear; impact seen with > 4 + nodes, but not 1 -3+
![Page 27: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/27.jpg)
®
Regional Node Irradiation (RNI):� All patients had ALND� SC and Axillary Apex
� IMN’s
MA.20 Study Design
N+ orhigh risk N - post-BCS
WBI
WBI + RNI
![Page 28: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/28.jpg)
MA.20 Patients
• BCS with clear margins
• All patients had a level I/II ALND
• 85% had 1-3 positive nodes
• 91% received adjuvant chemotherapy
• HR+ patients received hormonal rx
![Page 29: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/29.jpg)
5-Year Results
DFS LR DFS Distant DFS
Survival
WBI 84.0% 94.8% 87.3% 89.5%
WBI + RNI
89.7% 96.8% 91.6% 91.9%
P-value < 0.05 < 0.05 < 0.05 NS
![Page 30: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/30.jpg)
Hazard Rate (HR) Results
DFS LR DFS Distant DFS
Survival
HR 0.67 0.58 0.64 0.76
P-value 0.003 0.02 0.002 0.07
![Page 31: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/31.jpg)
MA.20
Need to see manuscript (currently at NEJM)
Results are striking, but a bit surprising: 1 –∆ DM = ∆ LRR
The recent results of the similar EORTC trial support MA.20 (European Cancer Congress)
![Page 32: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/32.jpg)
®
Regional Node Irradiation (RNI):� SC and Axillary Apex
� IMN’s
EORTC 22922/10925 Study Design
N+ or Medial N -post-BCS or Mastectomy
No RNI
RNI
![Page 33: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/33.jpg)
EORTC Patients
• 56% were N+ and 14.2% were stage III
• 76% had BCT
• 73% of mastectomy patients had CW RT
• Adjuvant systemic therapy in 99% of N+ patients and 66% of N - patients
• Median FU = 10.9 years
![Page 34: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/34.jpg)
Hazard Rate (HR) Results
DFS Distant DFS
Survival
HR 0.89 0.86 0.87
P-value 0.04 0.02 0.056
![Page 35: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/35.jpg)
Recent Trials of PMRT/RNI
• With routine adjuvant systemic therapy, these preliminary data suggest benefit to PMRT/RNI (in intermediate risk patients)
• Survival benefit not longer linked to reduction in LR
• Need RCT’s to assess survival benefit
![Page 36: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/36.jpg)
New Trials of Local Rx after NAC in U.S.
• NRG 9353
• Alliance A11101
![Page 37: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/37.jpg)
NRG 9353cT1-3N1M0 Axillary Node (+ by fna or core)
NAC + antiHer2 if HER2+
pN- (SNB or ALND)Randomized to
No Regional Nodal RTBreast RT alone if BCTNo CW RT if mastex
Regional Nodal RTWith breast if BCTCW RT if mastex
or
![Page 38: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/38.jpg)
Alliance A11101
cT1-3N1M0 Axillary Node (+ by fna or core)NAC + antiHer2 if HER2+
pN+ (SNB or ALND)Randomized to
Breast/CW + Regional Nodal RT
ALND andBreast/CW + Regional Nodal RT
or
![Page 39: Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC)€¦ · Post-Mastectomy RT after Neoadjuvant Chemotherapy (NAC) Jay R. Harris, M.D. Dana-Farber Cancer Institute Brigham and](https://reader035.vdocument.in/reader035/viewer/2022071012/5fca75bc67ae1d3498186f89/html5/thumbnails/39.jpg)
Conclusions
• When considering PMRT, use both initial clinical and final path stages
• If LABC, give PMRT even if pCR• If ypN+, give PMRT• If early stage with pCR, no PMRT
• After mastectomy, survival gain isn’t linked to LRR risk → need RCT’s